Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
出版年份 2018 全文链接
标题
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
作者
关键词
-
出版物
OncoImmunology
Volume 7, Issue 5, Pages e1421891
出版商
Informa UK Limited
发表日期
2017-12-29
DOI
10.1080/2162402x.2017.1421891
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
- (2017) Sanja Stevanović et al. SCIENCE
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- New Strategies in Breast Cancer: Immunotherapy
- (2016) L. Pusztai et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
- (2016) Stefani Spranger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition
- (2016) Liquan Gao et al. Theranostics
- Interferon- Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade
- (2016) M. J. McNamara et al. Cancer Immunology Research
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
- (2016) D. B. Page et al. Cancer Immunology Research
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer
- (2015) C. N. Johnstone et al. Disease Models & Mechanisms
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)
- (2015) Sylvia Adams et al. OncoImmunology
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Nivolumab for the treatment of cancer
- (2014) Anasuya Gunturi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
- (2014) Lidia Robert et al. OncoImmunology
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Treg and CTLA-4: Two intertwining pathways to immune tolerance
- (2013) Lucy S.K. Walker JOURNAL OF AUTOIMMUNITY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using synthetic templates to design an unbiased multiplex PCR assay
- (2013) Christopher S. Carlson et al. Nature Communications
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
- (2013) John Stagg et al. Therapeutic Advances in Medical Oncology
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
- (2012) X. Tai et al. BLOOD
- Generation of a Novel MMTV-tTA Transgenic Mouse Strain for the Targeted Expression of Genes in the Embryonic and Postnatal Mammary Gland
- (2012) Kazuhito Sakamoto et al. PLoS One
- Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma
- (2010) Katharina C. Kähler et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
- (2010) Elias A Said et al. NATURE MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 on dendritic cells impedes innate immunity against bacterial infection
- (2009) S. Yao et al. BLOOD
- Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells
- (2009) Hae-Yun Cho et al. IMMUNOLOGY LETTERS
- Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma
- (2008) Helena Hornychová et al. CANCER INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now